Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02498600 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

100

Enrollment

NIH

Sponsor class

Conditions

Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions

BIOLOGICAL: Ipilimumab
BIOLOGICAL: Nivolumab

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]